The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabien Tech. Regulatory News (SNT)

Share Price Information for Sabien Tech. (SNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.50
Bid: 12.00
Ask: 13.00
Change: 0.00 (0.00%)
Spread: 1.00 (8.333%)
Open: 12.50
High: 12.50
Low: 12.50
Prev. Close: 12.50
SNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

7 Jul 2021 07:00

RNS Number : 3698E
Sabien Technology Group PLC
07 July 2021
 

7 July 2021

 

Sabien Technology Group plc

("Sabien" or "the Company" or "the Group")

Trading Update

Sabien Technology Group plc (AIM:SNT), a company focused on building a portfolio of solutions in the heating, cooling, and transportation sectors, announces today a trading update ahead of the publication of its final results for the year ended 30 June 2021.

This trading update is published against a socio-economic background whose trends continue to support Sabien's strategic direction. As Governments in the US and Europe look to the post-COVID landscape, it is clear that changes in working locations, living conditions and transportation are all being actively accommodated. Extending its operations in and knowledge of the wider industrial heating markets, Sabien is actively pursuing targets within the non-refrigerant based cooling, battery recycling and reproduction, and waste to energy sectors together with a number of other "green energy" environmental opportunities in a variety of markets.

Sabien has raised £1.7m (gross) during the year to 30 June 2021. Through this financing, the Executive Chairman, Richard Parris, has further increased his position as a significant (10.3%) shareholder in the Company. Consistent with the strengthening of the Company's financial position, Sabien's issued shares were consolidated to provide a more representative basis for the Company's improved prospects. During this period, the Company exited the Reverse Take-Over (RTO) discussions with Ptarmigan Health Destinations and trading in its shares resumed on AIM.

In the first half of the 2021 financial year in comparison to the same period in the prior year, Sabien reported a near threefold increase in revenue and gross profit, substantially reducing the interim loss before tax and improving operational cash generation.

Strategically, the Company made an investment into Aeristech, a leading manufacturer of components for hydrogen fuel cells, secured a £400k contract with a UK Government department for the use of M2G technology, and formed a US subsidiary from which it will source US acquisition opportunities in addition to expanding the US market for Sabien's European products and services.

Since the publication of its interim results on 25 March 2021, the Company has made further considerable progress within its strategic development.

Operationally, Sabien has extended the application of its M2G technology with its Cloud-based subscription service now available across more than five sites within public sector, sports, and pharmaceutical manufacturing locations. Allied to this important development, Sabien has signed an agreement with Lockular to provide robust data security. Lockular's platform is agnostic as to which operations are contained on it and, as a result, this agreement provides scalability, Big Data collection and AI insights for further acquisitions which the Company may make, potentially decreasing the time required to generate value. In combination, these actions have given the Company confidence to commit to the next generation of M2G, integrating remote commercial boiler management within a single Cloud-enabled device.

Consistent with these developments throughout the year, and the Company's wider strategy, Sabien has strengthened its management team with the appointments of Danny Mills as President of the U.S. subsidiary,Sabien Inc., Dr. Athan Fox as Chief Scientific Officer and Tom Sprunt as Managing Director (non-Board). Mr. Mills is a US-based investor and technology operator who has worked with Sabien's leadership for a number of years. In combination with Richard Parris' work in US markets, Mr. Mills provides the necessary experience to benefit from President Biden's Plan for a Clean Energy Revolution and Environmental Justice. Dr. Fox's experience encompasses organic chemistry, intellectual property prosecution, technology transfer and fund raising for research, technology and innovation. Through Dr. Fox's work, Sabien is confident of a value-creating entry to the waste-to-energy market. Mr. Sprunt has many years' commercial experience in the boiler management industry.

In all cases, the new appointments bring a wealth of relevant experience and understanding of key markets for the Company.

Sabien's final results are expected to be published by the end of August 2021. The Board expects that these results will demonstrate the financial strength of the Company following the placing in February 2021. In addition, the Group has generated revenue of £0.97m in the year (2020: £0.45m), with £0.56m recorded in the second half, an increase of 89% on the £0.30m for the same period in the previous year. Sabien also carries circa £43k of open orders into FY22.

As at 30 June 2021, Sabien had cash in hand of £1.40m (2020: £0.78m).

Commenting on the 2021 financial year, Richard Parris, Chairman of Sabien, stated:

"The Board of Sabien faces an array of opportunities within its chosen market areas. In market capitalisation terms, Sabien is a small company listed on AIM. Executing an expansion strategy via acquisition can be challenging and expensive due to necessary market regulation. The Board will not be deterred by these challenges, and we are actively considering innovative structures within which to maximise the returns to shareholders as soon as possible while minimising execution expenses.

During the year under review, the Company has achieved already a number of key goals. From developing our core service, through strengthening the management team, to improving the Company's financial strength, the year to June 2021 has been one of progress. The Board looks forward to the coming year with considerable confidence. In addition to the number of exciting opportunities, several of which could come to fruition in the short to medium term, we are building a corporate structure which will ensure that this expansion delivers value to shareholders and maintains Sabien's ability to develop further. I look forward to reporting to shareholders in more detail in August."

 

For Further Information:

Sabien Technology Group plc

Richard Parris, Executive Chairman 

 

 +44 20 7993 3700 

Allenby Capital Limited (Nominated Adviser)

John Depasquale / Nick Harris 

 

 

+44 203 328 5656

 

Peterhouse Capital Limited (Broker)

Duncan Vasey / Lucy Williams 

 

+44 207 469 0930

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUNUBRAOUBRAR
Date   Source Headline
28th Nov 20185:49 pmRNSNotice of AGM
28th Nov 20185:29 pmRNSAnnual Financial Report
27th Nov 20183:21 pmRNSNotice of GM
23rd Nov 201812:07 pmRNSConditional placing and proposed board changes
19th Nov 20185:47 pmRNSHolding(s) in Company
30th Aug 20184:36 pmRNSResult of Meeting, Change of Registered Office
7th Jun 20187:00 amRNSCorporate Update New Order Received
2nd May 201810:51 amRNSTotal Voting Rights
27th Mar 20184:33 pmRNSPDMR Shareholding
26th Mar 20187:00 amRNSFundraise and appointment of sole broker
15th Mar 20182:42 pmRNSDirector/PDMR Shareholding
28th Feb 20185:34 pmRNSDirector/PDMR Shareholding
28th Feb 20185:32 pmRNSDirector Loan
14th Feb 20182:59 pmRNSResult of General Meeting
5th Feb 20184:22 pmRNSDirector/PDMR Shareholding
31st Jan 201812:33 pmRNSUnaudited Interim Results to 31 December 2017
19th Jan 20185:10 pmRNSNotice of General Meeting
29th Dec 201711:21 amRNSResult of AGM
7th Dec 20173:10 pmRNSNotice of AGM
7th Dec 20177:00 amRNSAudited Annual Report
1st Aug 20177:00 amRNSChange of Adviser
30th Jun 20177:01 amRNSFinance Director Retirement
30th Jun 20177:00 amRNSOrder Received
20th Apr 20174:45 pmRNSHolding(s) in Company
20th Apr 20174:03 pmRNSHolding(s) in Company
20th Apr 201711:15 amRNSHolding(s) in Company
20th Apr 201711:13 amRNSHolding(s) in Company
20th Apr 201711:11 amRNSHolding(s) in Company
18th Apr 20174:56 pmRNSTotal Voting Rights
18th Apr 201711:51 amRNSResult of GM
29th Mar 201710:00 amRNSNotice of GM
29th Mar 20177:30 amRNSResults of Placing
29th Mar 20177:00 amRNSHalf-year Report
30th Dec 201610:05 amRNSHolding(s) in Company
29th Nov 201612:19 pmRNSResult of AGM
29th Nov 201610:41 amRNSAGM Statement
7th Nov 20165:28 pmRNSNotice of AGM
25th Oct 20167:00 amRNSFinal Results
29th Sep 20163:25 pmRNSHolding(s) in Company
22nd Sep 20164:56 pmRNSHolding(s) in Company
22nd Sep 20164:54 pmRNSHolding(s) in Company
22nd Sep 20164:48 pmRNSHolding(s) in Company
16th Sep 20167:00 amRNS£750,000 Placing To Continue Growth Strategy
13th Jul 201610:47 amRNSResult of Meeting
13th Jul 20169:08 amRNSGM Statement
27th Jun 20169:42 amRNSNotice of GM
2nd Jun 20167:00 amRNSTrading Statement
3rd May 20167:00 amRNSUpdate on pilot programme
9th Feb 20167:00 amRNSHalf Yearly Report
6th Jan 20169:44 amRNSChange of name of Nominated Adviser and Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.